ECU-NMO 301
Brief description of study
A Phase 3 trial to evaluate the safety and efficacy of Eculizumab in the treatment of relapsing NMO. Target population must be 18 years and older, have a confirmed diagnosis of relapsing NMO, and have an EDSS score less than or equal to 7.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Neuromyelitis Optica
-
Age: Between 18 Years - 99 Years
-
Gender: All
Updated on
01 May 2019.
Study ID: 823411